Two inhibitor drugs, Enasidenib and Ivosidenib, targeting IDH1 and IDH2, respectively, were FDA approved for treatment of AML; the indication for Ivosidenib was extended to cholangiocarcinoma in 2023. This evidence concerns the gene IDH2 and acute myeloid leukemia.